```html

Westermark’s Disease – Complete Medical Guide

Overview

Westermark’s disease is not a recognized medical condition in modern textbooks. The term most frequently encountered in the literature actually refers to **Westermark’s sign**, a radiographic finding that indicates a reduction of pulmonary blood flow, classically associated with a pulmonary embolism (PE). Because patients and some online resources mistakenly label the entire disease process as “Westermark’s disease,” this guide will treat the phrase as a lay‑person’s way of describing a pulmonary embolism that exhibits Westermark’s sign on chest imaging.

Pulmonary embolism is a potentially life‑threatening blockage of one or more pulmonary arteries, usually caused by a blood clot that has traveled from the deep veins of the legs or pelvis. According to the U.S. Centers for Disease Control and Prevention (CDC), about 900,000 cases of venous thromboembolism (VTE) occur each year in the United States, with roughly 60 % presenting as PE. Worldwide, the incidence is estimated at 1–2 per 1,000 individuals per year (World Health Organization, 2022).

Symptoms

The clinical picture of PE can be highly variable, ranging from a sudden, catastrophic collapse to subtle, nonspecific discomfort. When Westermark’s sign is present on a chest X‑ray, the underlying embolus is typically sizable enough to cause noticeable symptoms.

Common Symptoms

• Sudden shortness of breath (dyspnea): Often the first and most prominent complaint.
• Chest pain: Typically sharp, pleuritic, and worsens with deep breathing or coughing.
• Rapid heart rate (tachycardia): Heart rate >100 beats/min in most acute cases.
• Cough: May be dry or produce blood‑streaked sputum (hemoptysis).
• Leg swelling or pain: Usually in the calf, indicating a deep‑vein thrombosis (DVT) source.

Less Common / Atypical Symptoms

• Light‑headedness or syncope
• Feeling of impending doom or anxiety
• Fever (usually low‑grade)
• Unexplained fatigue or malaise
• Abdominal pain (if embolus involves pulmonary arteries supplying the diaphragm)

Red‑Flag Symptoms Requiring Immediate Attention

• Sudden collapse or loss of consciousness
• Severe, worsening chest pain not relieved by rest
• Profuse coughing up blood
• Rapid, shallow breathing with a sense of suffocation

Causes and Risk Factors

PE is almost always a downstream event of a **venous thromboembolism**. The clot forms in the deep veins (most often of the lower extremities) and travels to the lungs.

Primary Causes

• Deep‑vein thrombosis (DVT): The immediate source of most emboli.
• Thrombus formation in the pelvic veins, right heart chambers, or upper extremities (e.g., after central line placement).

Major Risk Factors

• Prolonged immobility: Long‑distance travel, bed rest after surgery, or casting.
• Recent surgery or trauma: Especially orthopedic (hip/knee replacement) or major abdominal procedures.
• Cancer: Particularly active malignancies of the pancreas, lung, ovary, and brain; chemotherapy and hormonal therapy increase clot risk.
• Inherited or acquired clotting disorders: Factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome, deficiency of protein C, S, or antithrombin.
• Hormonal influences: Oral contraceptives, hormone replacement therapy, pregnancy, and the postpartum period.
• Obesity (BMI ≥ 30 kg/m²): Increases venous stasis.
• Smoking: Damages endothelium and promotes hypercoagulability.
• Age: Incidence rises sharply after age 60.
• Chronic medical conditions: Heart failure, inflammatory bowel disease, nephrotic syndrome.

Diagnosis

Because the presentation can mimic many other conditions (e.g., myocardial infarction, pneumonia, panic attack), a systematic approach is essential.

Clinical Assessment

• Detailed history of risk factors and symptom onset.
• Physical exam focusing on lung auscultation, heart rate, blood pressure, and assessment of lower‑extremity veins.

Risk‑Stratification Tools

The Wells Score and the Pulmonary Embolism Rule-out Criteria (PERC) help decide whether further testing is needed.

Imaging & Laboratory Tests

1. Chest X‑ray: Often the first study; may reveal Westermark’s sign—a focal area of oligemia (reduced blood flow) distal to an obstructed pulmonary artery. The sign is present in only ~2–4 % of PEs but is highly specific when seen.
2. D‑dimer assay: Highly sensitive; a normal result essentially rules out PE in low‑risk patients.
3. Computed Tomography Pulmonary Angiography (CTPA): Preferred definitive test; visualizes emboli directly with >95 % sensitivity.
4. Ventilation‑Perfusion (V/Q) scan: Used when CTPA is contraindicated (e.g., contrast allergy, renal failure).
5. Compression ultrasonography of the lower limbs: Detects DVT, supporting the diagnosis of PE.
6. Echocardiography: In massive PE, may show right‑ventricular dilation or pressure overload.

Treatment Options

Treatment aims to restore pulmonary perfusion, prevent clot propagation, and reduce recurrence risk.

Anticoagulation – The Cornerstone

• Initial (parenteral) therapy:
  • Low‑molecular‑weight heparin (LMWH) – e.g., enoxaparin 1 mg/kg subcutaneously every 12 h.
  • Unfractionated heparin (UFH) – IV infusion, titrated to an activated partial thromboplastin time (aPTT) of 1.5–2.5× control (useful in patients needing rapid reversal).
  • Fondaparinux – an indirect factor Xa inhibitor, once‑daily subcutaneous injection.
• Long‑term (oral) anticoagulation:
  • Direct oral anticoagulants (DOACs) – apixaban, rivaroxaban, edoxaban, or dabigatran (no bridging needed for apixaban or rivaroxaban).
  • Vitamin K antagonists (VKA) – warfarin, with an INR goal of 2.0–3.0 (requires bridging with LMWH/UFH for 5 days).
• Typical duration: 3 months for provoked PE, 6–12 months or indefinite for unprovoked or recurrent disease (per American College of Chest Physicians, 2021).

Thrombolytic Therapy

Reserved for high‑risk (massive) PE** with hemodynamic instability (systolic BP < 90 mmHg) or right‑ventricular failure. Options include:

• Alteplase (tPA) 100 mg IV over 2 h.
• Tenecteplase (single bolus) – studied in recent trials with comparable efficacy.

Contraindications (e.g., recent intracranial surgery, active bleeding) must be carefully ruled out.

Catheter‑Directed Therapies

• Mechanical fragmentation or aspiration thrombectomy.
• Low‑dose ultrasound‑assisted catheter‑directed thrombolysis (e.g., EKOS system).

These are options when systemic thrombolysis is contraindicated or when rapid clot removal is needed without severe bleeding risk.

Supportive Care

• Oxygen supplementation to keep SpO₂ > 94 %.
• Analgesia for pleuritic pain (acetaminophen or low‑dose opioids).
• Fluid management: cautious IV fluids to avoid worsening right‑ventricular overload.

Lifestyle & Secondary Prevention

• Graduated ambulation as soon as clinically safe.
• Compression stockings (30–40 mmHg) for patients with prior DVT to reduce post‑thrombotic syndrome.
• Smoking cessation, weight management, and regular physical activity.

Living with Westermark’s Disease

Even after successful treatment, many patients wonder how to return to normal life while minimizing recurrence.

Medication Adherence

• Take anticoagulants exactly as prescribed; set daily reminders.
• For warfarin, keep a diary of INR results and dietary vitamin K intake.
• DOACs do not require routine labs but should be reviewed if kidney function changes.

Regular Follow‑Up

• First follow‑up appointment 1‑2 weeks after hospital discharge to assess bleeding risk and therapy tolerance.
• Subsequent visits every 3 months for the first year, then annually if stable.

Physical Activity

• Begin with short walks; aim for at least 150 minutes of moderate‑intensity aerobic activity per week (CDC recommendation).
• Avoid high‑risk activities that involve prolonged sitting (e.g., long car trips) without periodic leg movement.

Travel Tips

• Wear graduated compression stockings during flights >4 hours.
• Perform calf‑muscle pumps every 1‑2 hours.
• Stay hydrated; avoid alcohol excess.

Psychological Well‑Being

Experiencing a PE can be frightening. Consider counseling, support groups, or anxiety‑management strategies. The CDC notes that stress management improves overall cardiovascular outcomes.

Prevention

Preventing the initial clot (or a repeat) focuses on mitigating stasis, endothelial injury, and hypercoagulability—the three components of Virchow’s triad.

• Mobility: Get up and move every 1–2 hours during long trips or hospital stays.
• Pharmacologic prophylaxis: Low‑dose LMWH, fondaparinux, or low‑dose aspirin for high‑risk surgical patients (per ACCP guidelines).
• Compression devices: Intermittent pneumatic compression boots for postoperative patients.
• Weight control and exercise: Maintain BMI < 30 kg/m².
• Manage comorbidities: Optimize control of diabetes, hypertension, and heart failure.
• Hormone considerations: Discuss alternatives to estrogen‑containing contraceptives or hormone therapy if you have other clot risk factors.

Complications

If untreated or inadequately managed, PE can lead to serious short‑ and long‑term sequelae.

Acute Complications

• Hemodynamic collapse: Cardiogenic shock due to right‑ventricular failure.
• Cardiac arrest.
• Hemoptysis.

Chronic Complications

• Chronic thromboembolic pulmonary hypertension (CTEPH): Persistent obstruction leads to pulmonary hypertension; occurs in 1–4 % of PE survivors (European Respiratory Society, 2020).
• Post‑thrombotic syndrome: Chronic leg swelling, pain, ulceration after DVT.
• Right‑ventricular dysfunction: Can persist and reduce exercise capacity.
• Psychological impact: Anxiety, depression, or post‑traumatic stress.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:

• Sudden, severe chest pain that is not relieved by rest or medication.
• Rapid, shallow breathing or feeling unable to catch your breath.
• Fainting, near‑fainting, or a feeling of “blackout.”
• Rapid heart rate ( >120 bpm) accompanied by low blood pressure.
• Coughing up a large amount of bright red blood.
• Sudden severe leg swelling, especially if accompanied by pain.

These signs may indicate a massive pulmonary embolism, which requires immediate life‑saving interventions.

---

References:

• Mayo Clinic. Pulmonary embolism. https://www.mayoclinic.org
• American College of Chest Physicians. Antithrombotic Therapy for VTE Disease: 2021 Clinical Practice Guidelines. Chest. 2021.
• World Health Organization. Global Health Estimates 2022.
• Centers for Disease Control and Prevention. Venous Thromboembolism (VTE) Data. 2023.
• European Respiratory Society. Chronic Thromboembolic Pulmonary Hypertension. 2020.
• NIH National Heart, Lung, and Blood Institute. Deep Vein Thrombosis and Pulmonary Embolism. 2022.
• Cleveland Clinic. Westermark Sign: What It Means. 2023.

```